The global HLA typing for transplant market is projected to reach USD 1.4 billion by 2030 from USD 1.1 billion in 2025, at a CAGR of 6.0% during the forecast period. The growth of the HLA typing market is being propelled by several key factors: the development of sophisticated HLA typing technologies, a rising demand for organ transplantation, strategic government efforts aimed at improving organ donation rates, and an expansion of research initiatives focused on HLA typing methodologies.
By technology, the molecular assays segment accounted for the largest market share in 2024.
The HLA typing for transplant market, by technology, is segmented into non-molecular and molecular assays. In 2024, the molecular assay technologies segment dominated the HLA typing market for transplants, reflecting a significant trend towards the utilization of molecular approaches among end users. This dominance is driven by a concerted emphasis from manufacturers on advancing high-resolution assays within molecular platforms, enhancing the accuracy and reliability of HLA typing for transplantation purposes.
By end user, the independent reference laboratories segment accounted for the largest market share in 2024
The HLA typing for transplant market is segmented based on end users into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2024, independent reference laboratories are projected to dominate the market, driven by a stronger inclination among diagnostic labs to outsource HLA typing services to biotech firms. This shift is facilitated by the advent of high-resolution molecular techniques and the rising number of strategic partnerships between reference laboratories and transplantation centers, enhancing service efficiency and diagnostic precision.
North America accounted for the largest market share, by region, in 2024.
In 2024, North America dominated the HLA typing market for transplant applications, closely followed by Europe. This trend can be attributed to several factors, including the availability of cutting-edge diagnostic technologies, a robust ecosystem of manufacturers, and a well-established healthcare infrastructure. Furthermore, the region is home to leading biotechnology firms that are active in the R&D of novel HLA alleles. Coupled with rising transplantation rates and supportive reimbursement frameworks, these elements significantly contribute to the market's expansion in North America.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1—20%, Tier 2—45%, and Tier 3—35%
• By Designation: C-level—35%, Directors—25%, and Others—40%
• By Region: North America—40%, Europe—30%, Asia Pacific—20%, Latin America—5%, and the Middle East & Africa—5%
Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Werfen (US), and TBG Biotechnology Corporation (Taiwan).
Research Coverage
This report studies the HLA typing for transplant market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes market opportunities and challenges for stakeholders and details the competitive landscape for market leaders. It is with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Rationale to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.
This report provides insights into the following pointers:
• Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
Market Development: Comprehensive information on lucrative emerging regions
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
圖表清單 List of Tables & Figures
TABLE 1 HLA TYPING FOR TRANSPLANT MARKET: INCLUSIONS & EXCLUSIONS 28
TABLE 2 HLA TYPING FOR TRANSPLANT MARKET ASSUMPTIONS 42
TABLE 3 HLA TYPING FOR TRANSPLANT MARKET: RISK ANALYSIS 43
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 59
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 59
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 59
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 8 HLA TYPING MARKET: ROLE IN ECOSYSTEM 64
TABLE 9 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR
HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 66
TABLE 10 HLA TYPING FOR TRANSPLANT MARKET: EXPORT SCENARIO FOR
HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 67
TABLE 11 HLA TYPING FOR TRANSPLANT MARKET: LIST OF MAJOR PATENTS/
PATENT APPLICATIONS 69
TABLE 12 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023–2024 (USD) 71
TABLE 13 AVERAGE SELLING PRICING TREND OF INSTRUMENTS AND REAGENTS,
BY REGION, 2022–2024 (USD THOUSAND) 72
TABLE 14 HLA TYPING FOR TRANSPLANT MARKET: PORTERS FIVE FORCES 74
TABLE 15 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 77
TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FOR MAJOR END USERS 78
TABLE 17 HLA TYPING FOR TRANSPLANT MARKET: LIST OF KEY CONFERENCES &
EVENTS, JANUARY 2025–DECEMBER 2026 78
TABLE 18 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING
HLA TYPING ACCURACY IN TRANSPLANTATION 79
TABLE 19 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION 79
TABLE 20 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING 80
TABLE 21 HLA TYPING FOR TRANSPLANT MARKET: UNMET NEEDS 83
TABLE 22 HLA TYPING FOR TRANSPLANT MARKET: KEY COMPANIES IMPLEMENTING AI 84
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES 85
TABLE 24 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 89
TABLE 25 HLA TYPING FOR TRANSPLANT MARKET FOR REAGENTS & CONSUMABLES,
BY REGION, 2023–2030 (USD MILLION) 90
TABLE 26 HLA TYPING FOR TRANSPLANT MARKET FOR INSTRUMENTS, BY REGION,
2023–2030 (USD MILLION) 91
TABLE 27 HLA TYPING FOR TRANSPLANT MARKET FOR SOFTWARE & SERVICES,
BY REGION, 2023–2030 (USD MILLION) 92
TABLE 28 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 94
TABLE 29 HLA TYPING FOR TRANSPLANT TECHNOLOGY MARKET, BY REGION,
2023–2030 (USD MILLION) 94
TABLE 30 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 95
TABLE 31 HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 96
TABLE 32 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION) 97
TABLE 33 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 97
TABLE 34 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION,
2023–2030 (USD MILLION) 98
TABLE 35 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION,
2023–2030 (USD MILLION) 99
TABLE 36 REAL-TIME PCR MARKET, BY REGION, 2023–2030 (USD MILLION) 100
TABLE 37 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 38 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 102
TABLE 39 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 102
TABLE 40 SANGER SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 41 NEXT-GENERATION SEQUENCING MARKET, BY REGION,
2023–2030 (USD MILLION) 104
TABLE 42 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 104
TABLE 43 HLA TYPING FOR TRANSPLANT MARKET FOR NON-MOLECULAR ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 105
TABLE 44 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 107
TABLE 45 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 107
TABLE 46 HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 108
TABLE 47 ANTIBODY SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 48 CHIMERISM MONITORING MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 49 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION,
2023–2030 (USD MILLION) 110
TABLE 50 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 111
TABLE 51 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE,
2023–2030 (USD MILLION) 113
TABLE 52 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION,
2023–2030 (USD MILLION) 114
TABLE 53 HLA TYPING FOR SOFT-TISSUE TRANSPLANTS MARKET, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 54 HLA TYPING FOR STEM CELL TRANSPLANTS MARKET, BY REGION,
2023–2030 (USD MILLION) 116
TABLE 55 HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 118
TABLE 56 HLA TYPING FOR TRANSPLANT MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2023–2030 (USD MILLION) 119
TABLE 57 HLA TYPING FOR TRANSPLANT MARKET FOR HOSPITALS &
TRANSPLANT CENTERS, 2023–2030 (USD MILLION) 120
TABLE 58 HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2023–2030 (USD MILLION) 121
TABLE 59 HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 60 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE,
2023 (NUMBER OF TRANSPLANTS) 123
TABLE 61 NORTH AMERICA: KEY MACROINDICATORS 124
TABLE 62 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 63 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 126
TABLE 64 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 126
TABLE 65 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 127
TABLE 66 US: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 128
TABLE 67 US: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 128
TABLE 68 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 128
TABLE 69 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 129
TABLE 70 CANADA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 130
TABLE 71 CANADA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 130
TABLE 72 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 130
TABLE 73 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 74 EUROPE: KEY MACROINDICATORS 132
TABLE 75 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 132
TABLE 76 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 133
TABLE 77 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 133
TABLE 78 EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 134
TABLE 79 GERMANY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 135
TABLE 80 GERMANY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 81 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 135
TABLE 82 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 83 UK: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 137
TABLE 84 UK: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 137
TABLE 85 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 137
TABLE 86 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 138
TABLE 87 FRANCE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 138
TABLE 88 FRANCE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 139
TABLE 89 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 139
TABLE 90 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 140
TABLE 91 SPAIN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 140
TABLE 92 SPAIN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 93 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 94 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 95 ITALY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 142
TABLE 96 ITALY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 97 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 143
TABLE 98 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 143
TABLE 99 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 144
TABLE 100 REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 144
TABLE 101 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 144
TABLE 102 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 103 ASIA PACIFIC: KEY MACROINDICATORS 146
TABLE 104 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 105 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 148
TABLE 106 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 149
TABLE 107 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 149
TABLE 108 CHINA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 150
TABLE 109 CHINA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 110 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 111 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 112 INDIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 152
TABLE 113 INDIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 114 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 115 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 116 JAPAN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 154
TABLE 117 JAPAN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 118 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 155
TABLE 119 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 155
TABLE 120 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 156
TABLE 121 AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 122 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 123 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 124 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 158
TABLE 125 SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 126 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 159
TABLE 127 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 128 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 160
TABLE 129 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 130 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 131 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 132 LATIN AMERICA: KEY MACROINDICATORS 162
TABLE 133 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 134 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 162
TABLE 135 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 163
TABLE 136 LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2023–2030 (USD MILLION) 163
TABLE 137 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 164
TABLE 138 BRAZIL: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 139 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 165
TABLE 140 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 165
TABLE 141 MEXICO: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 166
TABLE 142 MEXICO: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 143 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 144 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 145 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 168
TABLE 146 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 147 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 148 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 149 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 170
TABLE 150 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023–2030 (USD MILLION) 170
TABLE 151 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 171
TABLE 152 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 171
TABLE 153 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION) 172
TABLE 154 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 173
TABLE 155 GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 173
TABLE 156 GCC COUNTRIES: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE,
2023–2030 (USD MILLION) 173
TABLE 157 GCC COUNTRIES: SEQUENCING-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 158 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 174
TABLE 159 REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 160 REST OF MIDDLE EAST & AFRICA: PCR-BASED MOLECULAR ASSAYS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 161 REST OF MIDDLE EAST & AFRICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION) 176
TABLE 162 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN
HLA TYPING FOR TRANSPLANT MARKET 177
TABLE 163 HLA TYPING FOR TRANSPLANT MARKET: DEGREE OF COMPETITION 180
TABLE 164 HLA TYPING FOR TRANSPLANT MARKET: REGION FOOTPRINT 185
TABLE 165 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT & SERVICE FOOTPRINT 186
TABLE 166 HLA TYPING FOR TRANSPLANT MARKET: TECHNOLOGY FOOTPRINT 187
TABLE 167 HLA TYPING FOR TRANSPLANT MARKET: APPLICATION FOOTPRINT 187
TABLE 168 HLA TYPING FOR TRANSPLANT MARKET: END-USER FOOTPRINT 188
TABLE 169 HLA TYPING FOR TRANSPLANT MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 191
TABLE 170 HLA TYPING FOR TRANSPLANT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION 192
TABLE 171 HLA TYPING FOR TRANSPLANT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 195
TABLE 172 HLA TYPING FOR TRANSPLANT MARKET: DEALS, JANUARY 2022–APRIL 2025 196
TABLE 173 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 197
TABLE 174 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 198
TABLE 175 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS,
JANUARY 2022–APRIL 2025 199
TABLE 176 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–APRIL 2025 200
TABLE 177 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 201
TABLE 178 ILLUMINA, INC.: COMPANY OVERVIEW 202
TABLE 179 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 204
TABLE 180 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 204
TABLE 181 QIAGEN: COMPANY OVERVIEW 206
TABLE 182 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 207
TABLE 183 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 209
TABLE 184 QIAGEN: DEALS, JANUARY 2022–APRIL 2025 209
TABLE 185 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 211
TABLE 186 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 212
TABLE 187 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 213
TABLE 188 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 215
TABLE 189 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 216
TABLE 190 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–APRIL 2025 217
TABLE 191 CAREDX, INC.: COMPANY OVERVIEW 219
TABLE 192 CAREDX, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 220
TABLE 193 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 221
TABLE 194 CAREDX, INC.: DEALS, JANUARY 2022–APRIL 2025 221
TABLE 195 WERFEN: COMPANY OVERVIEW 222
TABLE 196 WERFEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 222
TABLE 197 WERFEN: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 223
TABLE 198 WERFEN: DEALS, JANUARY 2022–APRIL 2025 223
TABLE 199 DIASORIN S.P.A.: COMPANY OVERVIEW 224
TABLE 200 DIASORIN S.P.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 225
TABLE 201 DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 226
TABLE 202 TBG BIOTECHNOLOGY CORP.: COMPANY OVERVIEW 227
TABLE 203 TBG BIOTECHNOLOGY CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 227
TABLE 204 TBG BIOTECHNOLOGY CORP.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 228
TABLE 205 TBG BIOTECHNOLOGY CORP.: DEALS, JANUARY 2022–APRIL 2025 228
TABLE 206 FUJIREBIO: COMPANY OVERVIEW 229
TABLE 207 FUJIREBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 229
TABLE 208 FUJIREBIO: DEALS, JANUARY 2022–APRIL 2025 230
TABLE 209 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 231
TABLE 210 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 233
TABLE 211 EUROBIO SCIENTIFIC: COMPANY OVERVIEW 234
TABLE 212 EUROBIO SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 235
TABLE 213 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 235
TABLE 214 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022–APRIL 2025 236
TABLE 215 PACBIO: COMPANY OVERVIEW 237
TABLE 216 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 239
TABLE 217 PACBIO: PRODUCT APPROVALS AND UPDATES, JANUARY 2022–APRIL 2025 239
TABLE 218 PACBIO: DEALS, JANUARY 2022–APRIL 2025 240
TABLE 219 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW 241
TABLE 220 BAG DIAGNOSTICS GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED 241
TABLE 221 CREATIVE BIOLABS: COMPANY OVERVIEW 242
TABLE 222 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 242
TABLE 223 HISTOGENETICS LLC: COMPANY OVERVIEW 243
TABLE 224 SCISCO GENETICS, INC.: COMPANY OVERVIEW 244
TABLE 225 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW 245
TABLE 226 BIONOBIS: COMPANY OVERVIEW 246
TABLE 227 TAKARA BIO INC.: COMPANY OVERVIEW 247
TABLE 228 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW 248
TABLE 229 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW 249
TABLE 230 PROIMMUNE LTD.: COMPANY OVERVIEW 250
TABLE 231 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW 251
TABLE 232 BIOFORTUNA LIMITED: COMPANY OVERVIEW 252
FIGURE 1 HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & REGIONAL SCOPE 27
FIGURE 2 HLA TYPING FOR TRANSPLANT MARKET: YEARS CONSIDERED 29
FIGURE 3 HLA TYPING FOR TRANSPLANT MARKET: RESEARCH DESIGN 31
FIGURE 4 HLA TYPING FOR TRANSPLANT MARKET: KEY PRIMARY SOURCES 33
FIGURE 5 HLA TYPING FOR TRANSPLANT MARKET: KEY INSIGHTS FROM PRIMARIES 34
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND
DEMAND-SIDE PARTICIPANTS 34
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 35
FIGURE 8 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
FIGURE 9 MARKET SIZE ESTIMATION FOR HLA TYPING FOR TRANSPLANT MARKET:
COMPANY REVENUE ESTIMATION 37
FIGURE 10 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF
THERMO FISHER SCIENTIFIC INC. (2024) 38
FIGURE 11 HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE- AND PROCEDURE-BASED MARKET ESTIMATION APPROACH 39
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
FIGURE 13 HLA TYPING FOR TRANSPLANT MARKET: DATA TRIANGULATION 41
FIGURE 14 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE,
2025 VS. 2030 (USD MILLION) 44
FIGURE 15 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 45
FIGURE 16 HLA TYPING FOR TRANSPLANT MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 45
FIGURE 17 HLA TYPING FOR TRANSPLANT MARKET: REGIONAL SNAPSHOT 46
FIGURE 18 IMPROVED HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET 47
FIGURE 19 US AND REAGENTS & CONSUMABLES SEGMENT ACCOUNTED
FOR LARGEST MARKET SHARE IN 2024 48
FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES
DURING STUDY PERIOD 49
FIGURE 21 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 50
FIGURE 22 HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 51
FIGURE 23 HLA TYPING FOR TRANSPLANT MARKET: VALUE CHAIN ANALYSIS 61
FIGURE 24 HLA TYPING FOR TRANSPLANT MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 25 HLA TYPING FOR TRANSPLANT MARKET: ECOSYSTEM ANALYSIS 64
FIGURE 26 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR
HS CODE 3822 (2020–2024) 65
FIGURE 27 HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR
HS CODE 3822 (2020–2024) 67
FIGURE 28 HLA TYPING FOR TRANSPLANT MARKET: TOP PATENT APPLICANTS/
OWNERS (JANUARY 2014–DECEMBER 2025) 68
FIGURE 29 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE,
2023–2024 (USD THOUSAND) 70
FIGURE 30 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE,
2022–2024 (USD THOUSAND) 71
FIGURE 31 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY REGION,
2022–2024 (USD THOUSAND) 72
FIGURE 32 HLA TYPING FOR TRANSPLANT MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE 77
FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS 77
FIGURE 35 HLA TYPING FOR TRANSPLANT MARKET: TRENDS/DISRUPTIONS I
MPACTING CUSTOMERS’ BUSINESSES 81
FIGURE 36 HLA TYPING FOR TRANSPLANT MARKET: FUNDING AND NUMBER
OF DEALS, 2019–2023 81
FIGURE 37 HLA TYPING FOR TRANSPLANT MARKET: NUMBER OF DEALS,
BY KEY PLAYER, 2019–2023 82
FIGURE 38 HLA TYPING FOR TRANSPLANT MARKET: VALUE OF DEALS,
BY KEY PLAYER, 2019–2023 (USD) 82
FIGURE 39 AI USE CASES IN HLA TYPING FOR TRANSPLANT MARKET 84
FIGURE 40 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT 125
FIGURE 41 ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT 147
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING FOR
TRANSPLANT MARKET (2020–2024) 179
FIGURE 43 MARKET SHARE ANALYSIS OF PLAYERS IN HLA TYPING FOR
TRANSPLANT MARKET (2024) 180
FIGURE 44 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 183
FIGURE 45 HLA TYPING FOR TRANSPLANT MARKET: COMPANY FOOTPRINT 184
FIGURE 46 HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 190
FIGURE 47 EV/EBITDA OF KEY VENDORS 193
FIGURE 48 5-YEAR STOCK BETA OF KEY VENDORS 193
FIGURE 49 HLA TYPING FOR TRANSPLANT MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS 194
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 198
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT 203
FIGURE 52 QIAGEN: COMPANY SNAPSHOT 207
FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 212
FIGURE 54 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 216
FIGURE 55 CAREDX, INC.: COMPANY SNAPSHOT 220
FIGURE 56 DIASORIN S.P.A.: COMPANY SNAPSHOT 225
FIGURE 57 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 232
FIGURE 58 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT 234
FIGURE 59 PACBIO: COMPANY SNAPSHOT 238